Polyploid giant cancer cells: Unveiling a latent axis of resistance and tumor evolution in HER2-targeted therapy

Recent findings by Yazdi et al. in Cancer Letters present a mechanistic breakthrough in understanding resistance to HER2-targeting antibody-drug conjugates (ADCs). Their identification of drug-persistent polyploid giant cancer cells (PGCCs) as active participants in resistance redefines our understanding of intratumoral plasticity and therapeutic evasion. Far from being senescent relics, PGCCs function as epigenetically plastic reservoirs of tumor regeneration, capable of entering dormancy and re-seeding therapy-resistant clones. This commentary explores the mechanistic, evolutionary, and clinical implications of this phenomenon, urging a shift toward integrated therapeutic designs that disrupt the adaptive survival circuitry of PGCCs.